Key result
An acute oral phosphate load of 1200 mg did not significantly impact endothelium-dependent flow-mediated dilation (p=0.905) or endothelium-independent vasodilation in healthy young males.
Why the study?
Does an acute oral phosphate load impair endothelium-dependent and independent brachial artery vasodilation in healthy young males?
RCT (n=17)
Double-blind
Counterbalanced
No
Does an acute oral phosphate load impair endothelium-dependent and independent brachial artery vasodilation in healthy young males?
An acute oral phosphate load of 1200 mg does not significantly alter raw FMD or GTN-mediated vasodilation in healthy young males, though exploratory analyses suggest a potential transient impairment when adjusting for shear stress.
Acute phosphate load does not impair FMD in healthy young males; leaves open chronic effects or relevance in cardiovascular risk populations.
Serum phosphate levels are associated with cardiovascular morbidity and mortality in the general population and endothelial dysfunction may be mechanistically involved. The purpose of this study was to investigate the effects of acute phosphate supplementation on endothelial-dependent (flow-mediated dilation; FMD) and -independent (glyceryl trinitrate; GTN)) vasodilation in young, healthy males. Seventeen healthy male participants (age, 23 ± 3 years) were exposed to an oral load of phosphate (PHOS; liquid supplement containing 1200 mg of phosphorous) and placebo (PLAC) over 2 experimental days. A brachial artery FMD test was performed pre-ingestion and at 20 min, 60 min, and 120 min following the ingestion of the phosphate load or the placebo. GTN tests were performed pre- and 140 min post-ingestion. Serum phosphate was not impacted differently by phosphate versus placebo ingestion (p = 0.780). In contrast, urinary phosphate excretion was markedly increased in the PHOS (p < 0.001) but not in the PLAC condition (p = 0.130) (Δ fractional excretion of phosphate in PHOS (29.2%) vs. PLAC (9.3%)). This indicates that circulating phosphate levels were homeostatically regulated. GTN-mediated vasodilation was not significantly affected by phosphate ingestion. In primary analysis no impact of phosphate ingestion on FMD was detected. However, when the shear stress stimulus was added as a covariate in a subset of participants, exploratory pairwise comparisons revealed a significantly lower FMD 20 min post-phosphate ingestion versus placebo (p = 0.024). The effects of phosphate ingestion on FMD and serum phosphate are in contrast with previous findings and the mechanisms that underlie the disparate results require further investigation.
No takes yet. Share an insight, caveat, or question.
Levac et al. (2017) conducted an RCT in Healthy (n=17). Oral phosphate load vs. Placebo was evaluated on Endothelium-dependent vasodilation (%FMD) (p=0.905). An acute oral phosphate load of 1200 mg did not significantly impact endothelium-dependent flow-mediated dilation (p=0.905) or endothelium-independent vasodilation in healthy young males.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: